Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Peter Staley interviews Jules Levin, an activist and survivor of hepatitis C and HIV coinfection, ab
Peter Staley talks with long-term survivor Matt Sharp at ICAAC about his activism, his new regimen, and his facial lipo fix.
At the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Peter Staley a
Peter Staley talks with long-term survivor Matt Sharp about his activism, his new regimen, and his facial lipo fix.
Peter Staley asks Dr. Joe Eron about the latest data from the 47th Interscience Conference on Antimi
What women need to know about HIV and antivirals; how the drugs work differently in women than they do in men.
A combined analysis of two Phase III clinical trials of etravirine suggests that the drug is promising for treatment-experienced patients, whe...
Forty-eight weeks of therapy with Selzentry, combined with an optimized background regimen (OBR), is associated with greater viral load reduct...
Researchers once again reported promising results from an early study of PRO 140, an experimental HIV entry inhibitor.
Approximately two thirds of patients participating in Phase III studies of Pfizer’s Selzentry (maraviroc) who experience treatment failure hav...
Peter Staley asks Dr. Sharon Walmsley what women need to know about HIV and antivirals, and gender differences needing more research.
Schering-Plough’s vicriviroc may offer long-lasting viral load reductions in treatment-experienced patients who combine the drug with an optim...
An intriguing study suggests that periodic injections with interleukin-2 (IL-2) may allow HIV-positive patients to keep their CD4 counts high...
Peter Staley asks Dr. Joe Eron about the latest data on soon-to-be-approved Isentress and an entry inhibitor you might inject just once every...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.